Skip to content

The optimal dosage of oliceridine for anesthesia induction with Laryngeal Mask Airway in children: a randomized trial

The optimal dosage of oliceridine for anesthesia induction with Laryngeal Mask Airway in children: a randomized trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114334
Enrollment
Unknown
Registered
2025-12-10
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

40 µg/kg group:The dosage of oliceridine for anesthesia is 40 µg/kg
45 µg/kg group:The dosage of oliceridine for anesthesia is 50 µg/kg
50 µg/kg group:The dosage of oliceridine for anesthesia is 50 µg/kg
55 µg/kg group:The dosage of oliceridine for anesthesia is 55 µg/kg
60 µg/kg group:The dosage of oliceridine for anesthesia is 60 µg/kg

Sponsors

Guangzhou women and children's medical center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. Children undergoing laparoscopic hernia repair under general anesthesia with a laryngeal mask 2. ASA classification I-II 3. Aged 2-6 years old

Exclusion criteria

Exclusion criteria: 1. Children with allergies to the components of oliceridine; children with severe thrombocytopenia or gastrointestinal ulcers; 2. Children who used analgesic-sedative drugs, antiemetic drugs, and anti-itch drugs within 24 hours before surgery; 3. Children with symptoms of acute upper respiratory tract infection before surgery; 4. Children with a history of bronchial asthma; 5. Children with severe sleep apnea syndrome or arrhythmia; 6. Children with a history of abnormal recovery from surgical anesthesia; children with preoperatively assessed existing or potentially difficult airways; 7. Renal impairment (BUN and/or Cr > upper limit of normal value); liver function impairment (ALT and/or AST > 1.5 times the upper limit of normal value) 8. Children with relevant mental or neurological diseases, making it difficult to evaluate the analgesic effect; 9. Children with a history of chronic pain or long-term use of painkillers; 10. Children with other conditions that the researchers consider unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
LMA insertion conditions;

Secondary

MeasureTime frame
Bispectral Index(BIS);The Nociception Index(qNOX);postoperative nauese and vomiting;Heart rate, blood pressure;

Countries

China

Contacts

Public ContactYong Zhang

Guangzhou women and children's medical center

gzfezxzy@outlook.com+86 156 2644 5473

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026